Johanne Silvain MD, PhD
Pr Johanne Silvain is a Professor of Medecine at the Pierre et Marie Curie University, School of Medicine, Paris 6 (Sorbonne University) and an Interventional Cardiologist at the Institut de Cardiologie at the Pitié-Salpêtrière Hospital in Paris, France where he is the director of the coronary care unit.
Pr Silvain graduated (MD) from the Sorbonne University and has been following medical studies in France including at the Mount Sinaï Hospital, New York, USA, and a post-doctoral training (PhD) on molecular basis and genetic of thrombosis at University of Pennsylvania, School of Medicine, in Philadelphia, USA.
His research interests expand from mechanisms of thrombosis (thromboaspiration and thrombus composition) to treatment (anticoagulant and antiplatelets agents) as well as advancing treatments for acute coronary syndrome (ACS) and acute myocardial infarction (STEMI network, delay and Quality Care) and its consequences on bleeding and transfusion.
As an interventional cardiologist, his main expertise field is all sort of PCI from elective PCI , to primary PCI and Chronic Total Occlusion (CTO) , he is an expert radialist and also performed structural procedure with PFO/CIA Closure and left atrial appendage (LAA) closure.
He is author of more than 100 publications is sucha as the New England Journal of Medecine, Lancet, JAMA, BMJ, Circulation, JACC and European Heart Journal in his main research interest of acute coronary syndromes, interventional cardiology and antithrombotic drugs: http://www.ncbi.nlm.nih.gov/pubmed/?term=Silvain+J[Author
Johanne Silvain is a member of the ACTION study group (Allies in Cardiovascular Trials Initiatives and Organized Networks); an Academic Research Organization specialized in clinical trials (http://action-coeur.org/en/) led by the Professor Gilles Montalescot.
The latest publication of the ACTION group concerning Major Randomized Clinical Trials art the ATLANTIC trial (NEJM) , ARCTIC trial (NEJM) , the ACCOAST trial (NEJM) , the ABOARD trial (JAMA) , the ATOLL trial (Lancet), ALBATROSS trial (JACC) and the ANTARCTIC trial (Lancet).
Pr Silvain is actually the PI of the international randomized trial ALPHEUS on elective PCI (ticagrelor vs clopidogrel) which is enrolling patients in France, Algeria and the UEA.
To be completed